We also assessed the KRAS/CDK1 SL in cell models of pancreatic ductal adenocarcinoma (PDAC), a disease where where somatic KRAS mutations are prevalent in approximately 90% of cases [34]. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.